Cargando…
The new‐generation pan‐peroxisome proliferator‐activated receptor agonist IVA337 protects the liver from metabolic disorders and fibrosis
IVA337 is a pan‐peroxisome proliferator‐activated receptor (PPAR) agonist with moderate and well‐balanced activity on the three PPAR isoforms (α, γ, δ). PPARs are regulators of lipid metabolism, inflammation, insulin resistance, and fibrogenesis. Different single or dual PPAR agonists have been inve...
Autores principales: | Wettstein, Guillaume, Luccarini, Jean‐Michel, Poekes, Laurence, Faye, Patrick, Kupkowski, Francine, Adarbes, Vanessa, Defrêne, Evelyne, Estivalet, Céline, Gawronski, Xavier, Jantzen, Ingrid, Philippot, Alain, Tessier, Julien, Tuyaa‐Boustugue, Pascale, Oakley, Fiona, Mann, Derek A., Leclercq, Isabelle, Francque, Sven, Konstantinova, Irena, Broqua, Pierre, Junien, Jean‐Louis |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5678909/ https://www.ncbi.nlm.nih.gov/pubmed/29404476 http://dx.doi.org/10.1002/hep4.1057 |
Ejemplares similares
-
Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis
por: Ruzehaji, Nadira, et al.
Publicado: (2016) -
Reduction of lysosome abundance and GAG accumulation after odiparcil treatment in MPS I and MPS VI models
por: Tuyaa-Boustugue, Pascale, et al.
Publicado: (2023) -
Odiparcil, a potential glycosaminoglycans clearance therapy in mucopolysaccharidosis VI—Evidence from in vitro and in vivo models
por: Entchev, Eugeni, et al.
Publicado: (2020) -
The pan-PPAR agonist lanifibranor reduces development of lung fibrosis and attenuates cardiorespiratory manifestations in a transgenic mouse model of systemic sclerosis
por: Derrett-Smith, Emma, et al.
Publicado: (2021) -
Role of ciliary dysfunction in a new model of obesity and non-alcoholic steatohepatitis: the foz/foz mice
por: Poekes, Laurence, et al.
Publicado: (2014)